Literature DB >> 11743037

Does mammographic screening and a negative result affect attitudes towards future breast screening?

C H Drossaert1, H Boer, E R Seydel.   

Abstract

OBJECTIVES: To investigate the impact of an experience of a benign mammographic result on intention to seek medical help immediately in the case of breast abnormalities, and on intentions and thoughts about future participation in screening.
SETTING: The Dutch Breast Cancer Screening Programme for women aged 50-69.
METHODS: Subjects were women who were invited for an initial breast examination: 223 women filled out a questionnaire about 10 days before and about 6 weeks after their initial breast examination. To be able to control for possible test effects, another group of 293 women filled out a questionnaire only after mammography. Changes in thoughts and intentions were examined.
RESULTS: Most women were very satisfied with the course of their initial breast examination, although pain or discomfort was often mentioned. No clues to suggest false reassurance were found: more than 99% of the women would consider the possibility of breast cancer if they felt a lump in one of their breasts. In such a situation, most women intended to seek medical help within a week. These variables were not influenced by the experience of mammography with a benign result. In general, women were very positive about (repeat) participation, both before and after screening. After screening, the average woman perceived fewer costs in participating, and perceived her own ability to engage in future screening as higher. However, the experience of pain and anxiety during the initial screening did lead to reverse effects. Women who were less satisfied about their treatment by the staff were more likely to change their intentions to reparticipate in a negative way.
CONCLUSIONS: As, in general, women became more positive about regular participation after they had attended breast cancer screening, efforts to improve first round attendance must be continued. At the same time, the screening organisations must continue to prioritise the high level of client friendliness throughout the screening. No evidence for detrimental effects of screening through false reassurance among participants was found.

Entities:  

Mesh:

Year:  2001        PMID: 11743037     DOI: 10.1136/jms.8.4.204

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  6 in total

1.  Discrepant screening mammography assessments at blinded and non-blinded double reading: impact of arbitration by a third reader on screening outcome.

Authors:  Elisabeth G Klompenhouwer; Adri C Voogd; Gerard J den Heeten; Luc J A Strobbe; Vivianne C Tjan-Heijnen; Mireille J M Broeders; Lucien E M Duijm
Journal:  Eur Radiol       Date:  2015-04-18       Impact factor: 5.315

2.  Consistency in attitudes across cancer screenings in medically underserved minority populations.

Authors:  Susan J Shaw; James Vivian; Kathryn M Orzech; Cristina Huebner Torres; Julie Armin
Journal:  J Cancer Educ       Date:  2012-03       Impact factor: 2.037

3.  Model of outcomes of screening mammography: information to support informed choices.

Authors:  Alexandra Barratt; Kirsten Howard; Les Irwig; Glenn Salkeld; Nehmat Houssami
Journal:  BMJ       Date:  2005-03-08

Review 4.  Screening for breast cancer: an update for the U.S. Preventive Services Task Force.

Authors:  Heidi D Nelson; Kari Tyne; Arpana Naik; Christina Bougatsos; Benjamin K Chan; Linda Humphrey
Journal:  Ann Intern Med       Date:  2009-11-17       Impact factor: 25.391

5.  Quality of life valuations of mammography screening.

Authors:  Amy E Bonomi; Denise M Boudreau; Paul A Fishman; Evette Ludman; Amy Mohelnitzky; Elizabeth A Cannon; Deb Seger
Journal:  Qual Life Res       Date:  2008-05-20       Impact factor: 4.147

6.  Communicating the results of clinical research to participants: attitudes, practices, and future directions.

Authors:  David I Shalowitz; Franklin G Miller
Journal:  PLoS Med       Date:  2008-05-13       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.